Skip to Main Content
Pinar Ataca Atillia

Pinar Ataca Atilla, M.D.

Department:

Medicine

Division:

Transplantation and Cellular Therapy

Pinar Ataca Atillia
Message Send!
Send a Message

Roles

  • Research Assistant Professor
  • Biography

    Dr. Pinar Ataca Atilla joined the University of Miami’s Division of Transplantation and Cellular Therapy in 2024 as a Research Assistant Professor. She is a physician-scientist specializing in hematology, bone marrow transplantation, and cellular immunotherapy. Following her fellowship in hematology, she trained at the Baylor College of Medicine Center for Cell and Gene Therapy under the supervision of Dr. Malcolm Brenner and at the Fred Hutchinson Cancer Center under the supervision of Dr. Damian Green, focusing on adoptive cellular immunotherapies.

    Her current research investigates mechanisms of relapse and resistance following chimeric antigen receptor (CAR) T-cell therapy. She explores strategies to enhance CAR T-cell persistence, prevent antigen escape, and reduce treatment-related toxicity through genetic and immunologic engineering approaches. Her overarching goal is to translate mechanistic insights into safer, more durable, and broadly applicable cellular therapies for patients with hematologic malignancies.
  • Education & Training

    Education

    • 2008
      University of Hacettepe, Ankara, Turkey
      MD, Doctor of Medicine

    Post Graduate Training

    • 2020
      Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX
      Post-Doctoral Fellowship
    • 2017
      Ankara University, Ankara, Turkey
      Fellowship, Hematology
    • 2013
      Dokuz Eylul University, Izmir, Turkey
      Residency, Internal Medicine
  • Honors & Awards

      Loading...

      No result found

    • Research Interests

      Dr. Pinar Ataca Atilla’s research focuses on understanding and overcoming mechanisms of relapse, resistance, and toxicity in chimeric antigen receptor (CAR) T-cell therapy. Her work integrates genetic and immunologic engineering approaches to enhance CAR T-cell persistence, prevent antigen escape, and improve safety in hematologic malignancies. By combining mechanistic studies with translational preclinical models, her goal is to develop safer, more durable, and broadly applicable cellular immunotherapies.
    • Publications

      Loading...

      No result found

        Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.